The hepatitis B infection treatment market was valued at USD 4.16 Billion in 2025, driven by the rising cases of hepatitis infections and better diagnostic procedures across the 8 major markets. The market is anticipated to grow at a CAGR of 4.60% during the forecast period of 2026-2035 to achieve a value of USD 6.52 Billion by 2035. The market growth is driven by rising adoption of digital platforms, telemedicine, and point-of-care diagnostic tools to improve screening, linkage to care, and monitoring, particularly in underserved or rural populations.
Base Year
Historical Period
Forecast Period
The rising diagnosis rates and global vaccination drives will continue to support steady market expansion over the coming decade.
Emerging oral antivirals with improved safety profiles will likely shift treatment preferences and boost long-term adherence.
Many regions, especially in Asia and Africa, are witnessing increased availability of cost-effective generics, driving treatment access and fueling market demand.
Compound Annual Growth Rate
4.6%
Value in USD Billion
2026-2035
*this image is indicative*
Hepatitis B infection treatment focuses on suppressing the virus and preventing liver damage. According to the World Health Organization’s 2024 Global Hepatitis Report, hepatitis B diagnosis rates increased from 10% in 2019 to 13% in 2024, while treatment coverage rose from just 2% to 3% globally. Regionally, the WHO African Region bears the highest burden, accounting for 63% of new hepatitis B infections. However, only 18% of newborns receive the birth-dose vaccination, a critical intervention to prevent early transmission. In the Western Pacific Region (which accounts for 47% of global hepatitis B deaths) treatment coverage is only 23% among those diagnosed, far below levels needed to significantly reduce mortality. Current options include antiviral drugs like tenofovir and entecavir, immunomodulators, and supportive therapies. While no complete cure exists, long-term treatment can manage chronic cases effectively. Vaccination plays a vital role in prevention. Advancements in drug development, rising awareness, and government initiatives are expanding access to care.
Adoption of Gene-Editing Therapies to Boost Market Growth
Increasing demand for curative therapies and growing investment in gene-editing technologies are driving innovation in the landscape. For instance, in March 2025, Precision BioSciences announced that the U.S. FDA cleared its Investigational New Drug (IND) application for PBGENE-HBV, a meganuclease-edited in vivo therapeutic developed using its proprietary ARCUS® platform. The clearance enables expansion of the ELIMINATE-B trial into the U.S., marking the first investigational in vivo gene-editing therapy approved to enter a clinical trial for chronic hepatitis B in the country. This breakthrough positions gene-editing-based therapies as a promising frontier in the forecast period, likely shifting the market toward potentially curative treatments and attracting significant clinical and commercial interest.
Some of the notable trends include the use of combination therapies for enhanced efficacy of treatment, rise in clinical trials, focus on preventing the condition with prompt vaccination.
Hepatitis B Infection Treatment Market Report and Forecast 2026-2035 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Treatment Type
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Region
Chronic Type to Dominate the Share by Type
Chronic hepatitis B infection is poised to hold the largest market share by type due to its long-term nature and global prevalence, especially in regions like Asia and sub-Saharan Africa. The increasing burden of chronic cases requires ongoing treatment and monitoring, fuelling consistent demand for therapeutic drugs and diagnostics. With growing awareness and improved diagnosis rates, this segment is expected to drive market expansion through the forecast period, supported by government-led screening and vaccination programs.
Antiviral Drugs to Hold a Substantial Hepatitis B Infection Treatment Market Value for Segmentation by Treatment Type
Antiviral drugs will likely dominate the treatment type segment, driven by their effectiveness in suppressing hepatitis B virus replication and preventing disease progression. As per the analysis by Expert Market Research, the global antiviral drugs market is anticipated to grow at a CAGR of 4.10% during the forecast period of 2025-2034. These drugs, especially tenofovir and entecavir, are widely prescribed due to their safety profiles and long-term efficacy. With rising treatment accessibility and strong pipeline development, this segment will continue to grow. Increased funding for drug development and broader adoption in high-burden regions are key factors sustaining its leadership in the global market.
Oral Route to Dominate the Share by Route of Administration
The oral route is expected to hold the largest market share by route of administration, primarily due to patient preference, ease of use, and better compliance. Most antiviral hepatitis B treatments are available in oral formulations, which facilitate long-term therapy for chronic cases. The convenience of self-administration at home reduces hospital dependency, supporting broader access. Future market growth will be reinforced by the development of novel oral formulations with improved bioavailability and safety profiles.
The United States is expected to lead the market, driven by high awareness, advanced diagnostics, and strong pharmaceutical presence. Major players like Gilead and GlaxoSmithKline dominate with antivirals such as tenofovir and entecavir. Widespread screening programs, immigration from endemic regions, and robust insurance coverage support market growth. In Europe, Germany has a structured healthcare system and offers full reimbursement for hepatitis B therapies. The country emphasizes early diagnosis and consistent long-term management using antivirals. Public awareness and screening efforts are strong, and the presence of multinational pharmaceutical companies ensures access to the latest treatments.
The key features of the market report comprise clinical trials and pipeline analysis, patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Headquartered in the United Kingdom and operating as a subsidiary of Intas Pharmaceuticals (founded in 1984 in India), Accord Healthcare offers a wide range of affordable generic medicines, including treatments for hepatitis B. The company is known for its strong presence in oncology, cardiology, and infectious diseases. Its extensive manufacturing and R&D capabilities enable the timely development of antiviral drugs. Accord’s global distribution and compliance with international regulatory standards strengthen its role in hepatitis B infection management.
Founded in 1974 and based in Toronto, Canada, Apotex Inc. is a prominent pharmaceutical company now under the ownership of SK Capital Partners. It is known for producing high-quality generic medications across various therapeutic areas, including hepatitis B. Apotex offers cost-effective antiviral drugs and actively supplies healthcare systems globally. Its research-driven approach, coupled with consistent regulatory approvals, supports the development of reliable treatment options in the hepatitis B infection treatment landscape.
Established in 1986 and headquartered in Hyderabad, India, Aurobindo Pharma is a leading global pharmaceutical manufacturer with a strong presence in antiviral and infectious disease segments. The company’s hepatitis B portfolio includes key antiviral medications like tenofovir and lamivudine. Aurobindo’s vertically integrated business model, global regulatory compliance, and robust R&D infrastructure position it as a vital player in the hepatitis B treatment market, catering to both developed and emerging regions.
Founded in 1887 and headquartered in New York, USA, Bristol-Myers Squibb is a major biopharmaceutical company known for pioneering innovation in immunology, oncology, and virology. In the hepatitis B market, it is best known for Baraclude (entecavir), a leading antiviral therapy. BMS invests heavily in clinical research and strategic collaborations to advance its treatment offerings. With a focus on precision medicine and patient-centered care, the company remains a key contributor to hepatitis B treatment globally.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Gilead Sciences, Inc., GSK plc, Lupin, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Zydus Healthcare Limited.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share